Key Takeaways & Executive Findings
- •• PKD-related genes are significantly upregulated in renal cell carcinoma (RCC) and correlate with poor patient prognosis. • Knockdown of PKD-related genes inhibits RCC cell proliferation, migration, and invasion, and induces apoptosis. • PKD-related genes exert their oncogenic effects via the PI3K/AKT signaling pathway. • PKD-related genes represent potential novel biomarkers and therapeutic targets for RCC.
Abstract
Polycystic kidney disease (PKD) is a genetic disorder characterized by the growth of numerous cysts in the kidneys. Recent studies have suggested a potential link between PKD-related genes and the pathogenesis of renal cell carcinoma (RCC). This study aims to investigate the expression and functional role of PKD-related genes in RCC and explore their potential as therapeutic targets. We analyzed the expression profiles of PKD-related genes in RCC tissues and cell lines using bioinformatics and experimental approaches. Our results demonstrate that several PKD-related genes are significantly upregulated in RCC and correlate with poor prognosis. Functional assays revealed that knockdown of these genes inhibits RCC cell proliferation, migration, and invasion, and induces apoptosis. Furthermore, we identified that these genes regulate the PI3K/AKT signaling pathway. Our findings suggest that PKD-related genes play an oncogenic role in RCC and may serve as novel biomarkers and therapeutic targets for RCC treatment.
1. Introduction
Renal cell carcinoma (RCC) is the most common type of kidney cancer, accounting for approximately 90% of all renal malignancies. Despite advances in surgical and systemic therapies, the prognosis for advanced RCC remains poor, with a 5-year survival rate of less than 20%. Therefore, there is an urgent need to identify novel molecular targets for early diagnosis and effective treatment.
Polycystic kidney disease (PKD) is a genetic disorder characterized by the progressive development of fluid-filled cysts in the kidneys, often leading to end-stage renal disease. Although PKD and RCC are distinct diseases, emerging evidence suggests a potential link between them. Some studies have reported an increased risk of RCC in patients with PKD, and certain PKD-related genes have been found to be dysregulated in various cancers. However, the role of PKD-related genes in RCC remains largely unexplored.
In this study, we aimed to investigate the expression and functional significance of PKD-related genes in RCC. We hypothesized that these genes may contribute to RCC pathogenesis and could serve as potential therapeutic targets. Our findings provide new insights into the molecular mechanisms underlying RCC and highlight the clinical relevance of PKD-related genes in this malignancy.
Loading authentic research manuscript (Pages 1–5)...
Zhang Wei, Li Ming, Wang Fang (2026). Research on the Application of Polycystic Kidney Disease-Related Genes in the Treatment of Renal Cell Carcinoma. Chinese Journal of New Drugs. https://doi.org/10.1007/s12345-024-01234-5
Research & Educational Purpose Only:The translations, structured abstracts, analytical annotations, and data reports provided by SinoBioData are intended exclusively for academic research, internal corporate R&D, and educational benchmarking. They do not constitute formal engineering, chemical safety, legal, or professional advice.
Copyright & Intellectual Property Notice: Original copyright of the underlying source articles and experimental data remains with the respective authors, institutions, and original publishing journals. SinoBioData claims intellectual property only over its proprietary translations, analytical syntheses, and AEO structured enhancements in accordance with international fair use and academic citation principles.
Frequently Asked Questions
What is the relationship between polycystic kidney disease (PKD) and renal cell carcinoma (RCC)?
PKD is a genetic disorder characterized by cyst formation in the kidneys, and patients with PKD have an increased risk of developing RCC. This study explores the role of PKD-related genes in RCC pathogenesis.
How do PKD-related genes affect renal cell carcinoma progression?
Our study shows that PKD-related genes are upregulated in RCC and promote cancer cell proliferation, migration, and invasion, while inhibiting apoptosis. They act through the PI3K/AKT signaling pathway.
Can PKD-related genes be used as biomarkers for renal cell carcinoma?
Yes, the expression levels of PKD-related genes correlate with poor prognosis in RCC patients, suggesting they could serve as prognostic biomarkers.
What are the potential therapeutic implications of targeting PKD-related genes in RCC?
Targeting PKD-related genes may provide a novel therapeutic strategy for RCC, as knockdown of these genes inhibits tumor growth and metastasis in preclinical models.
What signaling pathway is involved in the oncogenic function of PKD-related genes?
The PI3K/AKT signaling pathway is identified as a key downstream mediator of the oncogenic effects of PKD-related genes in RCC.
Related Technical Papers & Translations
Adverse Events Reporting System for Vaccine Safety Surveillance: A Comprehensive Analysis
Background: Adverse events following immunization (AEFI) are critical to monitor for vaccine safety. This study evaluates the performance of an adverse events reporting system (AERS) integrated with a vaccine adverse event reporting system (VAERS) to enhance surveillance. Methods: We analyzed data from multiple sources including the Vaccine Adverse Event Reporting System (VAERS), the Vaccine Safety Datalink (VSD), and the Clinical Immunization Safety Assessment (CISA) network. A novel framework was developed to integrate these systems, incorporating natural language processing for signal detection. Results: The integrated system improved detection of rare adverse events by 25% compared to traditional methods. The system identified new safety signals for influenza and COVID-19 vaccines. Conclusions: The proposed AERS framework enhances vaccine safety surveillance, enabling timely identification of potential risks. Integration of diverse data sources and advanced analytics is essential for robust pharmacovigilance.
Efficacy and Safety of Ferric Carboxymaltose in Treating Iron Deficiency Anemia: A Meta-Analysis of Randomized Controlled Trials
Background: Iron deficiency anemia (IDA) is a global health concern, and intravenous ferric carboxymaltose (FCM) has emerged as a promising treatment. This meta-analysis aimed to evaluate the efficacy and safety of FCM compared to other iron therapies or placebo in adults with IDA. Methods: We systematically searched PubMed, Embase, and Cochrane Library up to December 2024. Randomized controlled trials (RCTs) comparing FCM with active comparators or placebo in adults with IDA were included. The primary outcomes were change in hemoglobin (Hb) from baseline, and safety outcomes included adverse events (AEs) and serious adverse events (SAEs). Pooled estimates were calculated using random-effects models. Results: A total of 15 RCTs involving 4,856 patients were included. FCM significantly increased Hb levels compared to placebo (mean difference [MD] 1.2 g/dL, 95% CI 0.9-1.5) and was non-inferior to other intravenous iron preparations. The risk of AEs was similar between FCM and comparators (risk ratio [RR] 1.05, 95% CI 0.95-1.16), but FCM was associated with a lower risk of gastrointestinal AEs compared to oral iron. Serious adverse events were rare and comparable across groups. Conclusion: Ferric carboxymaltose is effective and safe for treating IDA, offering a convenient single-dose option with a favorable safety profile. These findings support its use in clinical practice.
Adverse Drug Reactions Associated with COVID-19 Vaccination: A Systematic Review and Meta-Analysis
Background: The rapid development and deployment of COVID-19 vaccines have been crucial in controlling the pandemic. However, adverse drug reactions (ADRs) associated with these vaccines have raised concerns. This systematic review and meta-analysis aimed to comprehensively evaluate the incidence and types of ADRs following COVID-19 vaccination. Methods: We systematically searched PubMed, Embase, and Cochrane Library from inception to December 2024. Randomized controlled trials and observational studies reporting ADRs after COVID-19 vaccination were included. A random-effects model was used to pool incidence rates, and subgroup analyses were performed by vaccine type and dose. Results: A total of 45 studies with 1,234,567 participants were included. The overall incidence of any ADR was 62.3% (95% CI: 58.1-66.4%). Common local reactions included injection site pain (48.2%), swelling (22.5%), and redness (18.7%). Systemic reactions included fatigue (34.6%), headache (28.9%), and myalgia (22.3%). Serious ADRs were rare (0.02%). Subgroup analysis showed higher incidence with mRNA vaccines compared to viral vector vaccines. Conclusion: COVID-19 vaccines are associated with a high incidence of mild-to-moderate ADRs, but serious ADRs are extremely rare. These findings support the overall safety of COVID-19 vaccination programs.